Mineralys publishes ESH 2026 presentation on lorundrostat in CKD hypertension trial

Mineralys Therapeutics

Mineralys Therapeutics

MLYS

0.00
  • Mineralys published an ESH 2026 presentation on lorundrostat for hypertension in chronic kidney disease, reporting results from the LAUNCH-HTN trial.
  • Primary endpoint: ambulatory office systolic blood pressure fell 16.9 mmHg at 6 weeks on lorundrostat 50 mg; placebo-adjusted decline was 9.1 mmHg.
  • Predefined 12-week endpoint: ambulatory office systolic blood pressure fell 19.0 mmHg; placebo-adjusted decline was 11.6 mmHg.
  • CKD subgroup analysis included 192 participants with baseline eGFR under 60 mL/min/1.73m² or UACR at least 30 mg/g, out of 800 with baseline renal data.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief on May 30, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.